D-0591-2025 Class II Ongoing
FDA drug recall D-0591-2025 was initiated by PFIZER INC on Aug 4, 2025 and is designated Class II. Reason for recall: Lack of Assurance of Sterility. The recall status is ongoing. Affected quantity: 15,750 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 27, 2025
- Initiation Date
- Aug 4, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 15,750 vials
Product description
Vial Label: 8.4% Sodium Bicarbonate Injection, USP, 50mEq/50 mL (1 mEq/mL), Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-6637-24. Case NDC: 00409-6637-14.
Reason for recall
Lack of Assurance of Sterility.
Distribution pattern
U.S. Nationwide
Code information
Lot #: LH2671, Exp. 11/30/2026
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0591-2025
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for PFIZER INC? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.